Han Jun, Meng Qingyang, Xi Qiulei, Wang Haiyu, Wu Guohao
Cancer Biomark. 2017;18(3):249-256. doi: 10.3233/CBM-160143.
Gastric cancer is one of the most common cancers worldwide, and the prognosis is still very poor due to the lack of specific and sensitive biomarkers. Aerobic glycolysis is one of the critical hallmarks of gastric cancer cells, and several glycolytic enzymes are highly expressed in gastric cancer patients. However, the expression and clinical significances of phosphofructokinase-2/fructose-2,6-bisphosphatase3 (PFKFB3, one of the glycolytic enzymes) in a large sample of gastric cancer patients remain unclear.
The expression of PFKFB3 was detected in 134 gastric cancer patients by qRT-PCR, immunohistochemistry, and western blot analyses. The correlation between PFKFB3 expression and clinicopathological factors was analyzed by χ 2 test. In addition, we also analyzed whether the knockdown of PFKFB3 by siRNAs could inhibit the ability of gastric cancer cells (MGC-803 and AGS) to proliferate and migrate by MTT analysis and transwell analyses.
PFKFB3 was highly expressed in 81.3% (109/134) of gastric cancer patients. The overexpression of PFKFB3 was associated with lymph node metastasis (P = 0.045) and TNM stage (P = 0.033). Knockdown of PFKFB3 by siRNAs significantly inhibited the proliferation and migration abilities of gastric cancer cells.
Our data suggest that PFKFB3 might be a potential biomarker for gastric cancer and anti-neoplastic targeting gene.
胃癌是全球最常见的癌症之一，由于缺乏特异性和敏感性生物标志物，其预后仍然很差。有氧糖酵解是胃癌细胞的关键特征之一，几种糖酵解酶在胃癌患者中高表达。然而，磷酸果糖激酶-2/果糖-2,6-二磷酸酶3（PFKFB3，一种糖酵解酶）在大量胃癌患者中的表达及临床意义仍不清楚。
通过qRT-PCR、免疫组织化学和蛋白质印迹分析检测134例胃癌患者中PFKFB3的表达。采用χ2检验分析PFKFB3表达与临床病理因素之间的相关性。此外，我们还通过MTT分析和Transwell分析，分析了siRNAs敲低PFKFB3是否能抑制胃癌细胞（MGC-803和AGS）的增殖和迁移能力。
81.3%（109/134）的胃癌患者中PFKFB3高表达。PFKFB3的过表达与淋巴结转移（P = 0.045）和TNM分期（P = 0.033）相关。siRNAs敲低PFKFB3可显著抑制胃癌细胞的增殖和迁移能力。
我们的数据表明，PFKFB3可能是胃癌的潜在生物标志物和抗肿瘤靶向基因。
